WO2007059916A2 - Composition pharmaceutique - Google Patents

Composition pharmaceutique Download PDF

Info

Publication number
WO2007059916A2
WO2007059916A2 PCT/EP2006/011138 EP2006011138W WO2007059916A2 WO 2007059916 A2 WO2007059916 A2 WO 2007059916A2 EP 2006011138 W EP2006011138 W EP 2006011138W WO 2007059916 A2 WO2007059916 A2 WO 2007059916A2
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
tablet
coating
lactamase inhibitor
solution
Prior art date
Application number
PCT/EP2006/011138
Other languages
English (en)
Other versions
WO2007059916A3 (fr
Inventor
Franz Xaver Schwarz
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of WO2007059916A2 publication Critical patent/WO2007059916A2/fr
Publication of WO2007059916A3 publication Critical patent/WO2007059916A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems

Definitions

  • the present invention belongs to the field of pharmaceutical industry and relates to novel medicaments for treatment of bacterial infections comprising a ⁇ -lactam antibiotic and a beta-lactamase inhibitor.
  • Combinations of ⁇ -lactam antibiotic and a ⁇ -lactamase inhibitor include for example the combination of amoxycillin trihydrate and potassium clavulanate which is widely used for treating bacterial infections.
  • Preferred dosage forms are conventional immediate release tablets and powder mixtures for reconstitution into paediatric aqueous suspensions like flavoured syrup.
  • Potassium clavulanate is extremely moisture sensitive to hydrolysis and requires manufacturing in very dry conditions. Therefore dosage forms are generally manufactured simply by mixing dry ingredients together or by dry compacting and compressing the material into tablets.
  • the tablets are generally coated with a polymer film coating, which may be applied from aqueous or organic solvent medium.
  • ⁇ -lactamase inhibitor protects ⁇ -lactam antibiotic from degradation by ⁇ -lactamase enzymes. Therefore the ⁇ -lactamase inhibitor should preferably be available at the desired site of action before the antibiotic to ensure immediate protection of the antibiotic.
  • Amoxicillin trihydrate and potassium clavulanate differ substantially with respect to their solubility in water.
  • Potassium clavulanate has significantly better solubility compared to most beta lactam antibiotics.
  • Potassium clavulanate is very water soluble and amoxycillin trihydrate is relatively insoluble. For this reason dosage forms such as suspensions, sachet granulates, dispersible tablets, which are dissolved in water shortly before administration by being stirred in water, are preferable to conventional tablets wherefrom both active substances are released simultaneously.
  • This problem could also be resolved by a tablet having a coating that contains the ⁇ - lactamase inhibitor and is dissolved in the stomach before the tablet core begins to break down.
  • the new process also enables to prepare tablets with slow release of the ⁇ - lactamase antibiotic without influencing the dissolution of the potassium clavulanate.
  • a part of the potassium clavulanate can be incorporated in the core of the tablet, allowing a part of it to be dissolved very quickly and another part to be dissolved simultaneously with the antibiotic. This would allow clavulanic acid to protect the amoxycillin immediately as soon as it releases from the formulation and before it reaches the absorption side.
  • the present invention provides a pharmaceutical solid dosage form comprising ⁇ -lactam antibiotic and having a film coating comprising ⁇ -lactamase inhibitor.
  • the dosage form of the invention may be a tablet or multi-units dosage form. Multi-units dosage form may comprise small film coated tablets or coated pellets, ⁇ -lactamase inhibitor may be present in the coating of the tablets or in the coating of the pellets. Optionally a part of ⁇ -lactamase inhibitor may be also present in the tablet core.
  • the dosage form of the invention may consist of one coated tablet, of 1 to 10 small coated tablets, or a desired quantity of coated pellets.
  • Preferable dosage form of the present invention is a film coated tablet comprising ⁇ - lactam antibiotic in the tablet core and ⁇ -lactamase inhibitor present in the tablet coating.
  • Suitable ⁇ -lactam antibiotics include antibiotically active penicillins, cephalosporins, monobactams or carbapenems, including their pharmaceutically acceptable salts and solvates such as hydrates.
  • the composition of the tablet core may allow immediate or modified (slow, controlled, or more phases) release of ⁇ -lactam antibiotic.
  • the tablet core as used herein relates to an uncoated tablet, comprising ⁇ -lactam antibiotic and optionally ⁇ -lactamase inhibitor and excipients.
  • the tablet core according to the present invention may include beside active ingredients pharmaceutically acceptable excipients, e.g. binders, fillers, disintegrants, releasing agents, lubricants which are standard in the preparation of tablets.
  • pharmaceutically acceptable excipients e.g. binders, fillers, disintegrants, releasing agents, lubricants which are standard in the preparation of tablets.
  • Diluents may be selected from a group consisting of calcium monocarbonate, calcium phosphate dibasic dihydrate, calcium phosphate tribasic, dextrates, dextrin, lactose, maltodextrin and sucrose.
  • Glidants may be selected from the group consisting of glyceryl stearate, talc and glyceryl behenate.
  • Lubricants may be selected from the group consisting of glyceryl behenate, glyceryl di/tripalmitostearate, hydrogenated vegetable oil, magnesium stearate, polyethylene glycol, potassium benzoate, sodium benzoate, sodium stearyl fumarate, tribehenin, zinc stearate.
  • Binders may be selected from corn starch pregelatinized, microcrystalline cellulose, starch pregelatinized, lactose monohydrate.
  • Disintegrants may be selected from the group consisting of maltose, sodium starch glycolate, maltodextrin, D-Mannitol, croscarmelose sodium, alginic acid, cellulose sodium starch glycolate and crospovidone.
  • the tablet core may additionally include releasing agents like alginates, xanthan gum, ethyl cellulose (EC), hydroxypropylmethyl cellulose (HPMC), methylcellulose, polyvinyl acetate phthalate, carboxymethy hydroxyethyl cellulose, carboxymethylmethyl cellulose, methacrylic acid copolymer, ethyl acrylate/methyl methacrylate copolymer, ammonio methacrylate copolymer and mixtures thereof.
  • releasing agents like alginates, xanthan gum, ethyl cellulose (EC), hydroxypropylmethyl cellulose (HPMC), methylcellulose, polyvinyl acetate phthalate, carboxymethy hydroxyethyl cellulose, carboxymethylmethyl cellulose, methacrylic acid copolymer, ethyl acrylate/methyl methacrylate copolymer, ammonio methacrylate copolymer and mixtures thereof.
  • the tablet cores may be obtained by conventional manufacturing techniques, e.g. by mixing ingredients together and compressing into tablet cores or by dry compacting (slugging or roller compaction) a part of excipients, adding the remaining excipients and compressing the material into tablet cores.
  • dry compacting slugging or roller compaction
  • a part of excipients adding the remaining excipients and compressing the material into tablet cores.
  • a film coating which is applied to the tablet core comprises ⁇ -lactamase inhibitor.
  • Suitable ⁇ -lactamase inhibitors are ⁇ -lactamase inhibitors which, when combined with one or more ⁇ -lactam antibiotics may result in improved in vivo activity of ⁇ - lactam antibiotic.
  • Such ⁇ -lactamase inhibitors include clavulanic acid in the form of a salt, such as potassium salt, tazobactam and sulbactam.
  • Preferable ⁇ -lactamase inhibitor is potassium clavulanate.
  • the coating mixture according to the present invention may comprise film-forming polymers selected from the group comprising ethyl cellulose (EC), hydroxypropylmethyl cellulose (HPMC), methylcellulose, polyvinyl acetate phthalate, carboxymethy hydroxyethyl cellulose, carboxymethylmethyl cellulose, methacrylic acid copolymer, ethyl acrylate/methyl methacrylate copolymer, ammonio methacrylate copolymer and mixtures thereof, preferably a mixture of ethyl EC and HPMC.
  • Ethylcellulose may be used as Aquacoat RCD.
  • the coating may further comprise other excipients such as plasticizers, glidants and pigments like titandioxid.
  • Plasticizer may be selected from the group of triacetin, tributyl citrate, acetylated hydrogenated cotton seed glyceride, acetylated hydrogenated soybean oil glycerides, acetyl triethyl citrate, and triethyl citrate.
  • Suitable glidant may be selected from glyceryl stearate, talk and glyceryl behenate.
  • the coating solution may be obtained e.g. by dissolving film-forming and other inactive ingredients in water, cooling the obtained solution to -5 to 15 °C and dissolving potassium clavulanate in the cooled solution.
  • the coating solution is sprayed onto the preheated tablet cores until the tablet cores are uniformly covered with the coating. Thickness of the coating depends on the dosage of ⁇ -lactamase inhibitor.
  • the present invention provides a solid dosage form comprising amoxicillin and clavulanic acid.
  • the dosage form may consist of one coated tablet, of 1 to 10 small coated tablets, or a desired quantity of coated pellets.
  • Clavulanic acid is present in the coating of tablets or pellets and optionally in the tablet cores.
  • Preferable dosage form is a tablet comprising amoxicillin in the core and clavulanic acid in the coating and optionally part of it in the core.
  • Amoxicillin may be in the form of amoxycillin trihydrate, anhydrous amoxicillin and alkali metal salts of amoxicillin such as sodium amoxicillin or a combination thereof. A combination of amoxicillin trihydrate and sodium amoxicillin may be used.
  • clavulanic acid is used in the form of potassium clavulanate.
  • Ratio of amoxycillin to clavulanate in the dosage form of the invention may vary between 2:1 and 30:1.
  • the ratio may be between 4:1 to 16:1 , preferably 4:1 , 7:1 , 8:1 , 16:1.
  • the amount of amoxicillin per dose may be between 125 and 3000 mg, preferably between 250 and 2000 mg.
  • the amount of the clavulanate inside the core may be between 1 to 95 % , preferably 10 to 50 %.
  • the tablets of the invention may be administered once, twice or three times daily.
  • the present invention provides a process for the preparation of solid dosage forms of the invention, particularly a process for coating tablet or pellet cores with a coating comprising potassium clavulanate.
  • Preparation of tablet cores may comprise granulating amoxicillin with aqueous solution of binder (starch, povidone, cellulose derivates ), sieving and drying the obtained granulate in a fluidized bed dryer, mixing the granulate with other excipients and pressing into tablet cores.
  • binder starch, povidone, cellulose derivates
  • the process of coating tablet cores comprises the following steps:
  • the coating solution is sprayed onto the preheated (30 to 60 0 C) tablet cores until the tablet cores are uniformly covered with the coating.
  • Weight of the coating depends on the dosage of clavulanate in the coating and may vary from 0.5 to 25 % of the core weight.
  • Preheated tablet cores may be coated in a coating pan which rotates at 6 to 12 rpm.
  • a fluidbed coater e.g. Glatt WSG Coater, H ⁇ ttlin Coater
  • Glatt WSG Coater H ⁇ ttlin Coater
  • the inlet air may be in the range 50 - 100 0 C, atomising air pressure 2 -8 bar.
  • the present invention provides a process for the preparation of tablet formulation comprising ⁇ -lactam antibiotic in the coating, said process comprises the following steps:
  • Example 1 1000/125 mg Tablet
  • Amoxicillin is granulated with an aqueous (1) solution of Kollidon 25, sieved, dried in a fluidized bed dryer, and equalized with another sieve.
  • the mixture is mixed with cellulose microcrystalline PH102, polyplasdone XL-10, silicon dioxide colloidal and magnesium stearate in a gravity mixer and pressed into tablets.
  • Hydroxypropylmethyl cellulose is dissolved in water (2), ethyl cellulose dispersion, ethyl citrate, talc and titanium dioxide are stirred in. The resulting film solution is cooled to 5°C. Then potassium clavulanate is dissolved in the solution.
  • the film solution is sprayed onto the preheated tablets in an Accela Cota.
  • the film- coated tablets are dried with very dry air ( ⁇ 5% moisture) after the coating process.
  • Amoxicillin DC, potassium clavulanate, silicon dioxide colloidal, cellulose microcrystalline PH 102 and magnesium stearate are mixed in gravity mixer and pressed into tablets.
  • Potassium clavulanate is dissolved in water (2) at a temperature of 5°C. Hydroxypropylmethyl cellulose is dissolved in water (3), ethyl cellulose dispersion, ethyl citrate, talc and titanium dioxide are stirred in.
  • the potassium clavulanate solution and then the film solution are sprayed onto the preheated tablets in an Accela Cota.
  • the resulting film-coated tablets are dried with very dry air ( ⁇ 5% moisture) after the coating process.
  • Amoxicillin DC, potassium clavulanate, silicon dioxide colloidal, cellulose microcrystalline PH 102 and magnesium stearate are mixed in gravity mixer and pressed into tablets.
  • Hydroxypropylmethyl cellulose is dissolved in water (2), ethyl cellulose dispersion, ethyl citrate, talc and titanium dioxide are stirred in. The resulting film solution is cooled to 5°C. Then potassium clavulanate is dissolved in the solution.
  • the film solution is sprayed onto the preheated tablets in an Accela Cota.
  • the resulting film-coated tablets are dried with very dry air ( ⁇ 5% moisture) after the coating process.
  • Amoxicillin, sodium amoxicillin, cellulose, xanthan gum microcrystalline PH102 are compacted together, and screened.
  • the granules are mixed with magnesium stearate in a gravity mixer and pressed into tablets.
  • Hydroxypropylmethyl cellulose is dissolved in water (2), ethyl cellulose dispersion, ethyl citrate, talc polyglycol and titanium dioxide are stirred in. The resulting film solution is cooled to 5°C. Then potassium clavulanate is dissolved in the solution.
  • the film solution is sprayed onto the preheated tablets in an Accela Cota.
  • the resulting film-coated tablets are dried with very dry air ( ⁇ 5% moisture) after the coating process.

Abstract

La présente invention concerne une nouvelle forme posologique solide qui comprend un antibiotique β-lactame et un inhibiteur de β-lactamase, l’inhibiteur de β-lactamase étant présent dans le revêtement en film. La nouvelle forme posologique peut être sous forme d’un comprimé enrobé ou d’une forme posologique à unités multiples qui comprend des particules enrobées.
PCT/EP2006/011138 2005-11-23 2006-11-21 Composition pharmaceutique WO2007059916A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200500321 2005-11-23
SIP-200500321 2005-11-23

Publications (2)

Publication Number Publication Date
WO2007059916A2 true WO2007059916A2 (fr) 2007-05-31
WO2007059916A3 WO2007059916A3 (fr) 2008-01-10

Family

ID=38015346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/011138 WO2007059916A2 (fr) 2005-11-23 2006-11-21 Composition pharmaceutique

Country Status (1)

Country Link
WO (1) WO2007059916A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014033077A1 (fr) 2012-08-28 2014-03-06 Dsm Sinochem Pharmaceuticals Netherlands B.V. Composition comprenant un antibiotique et un inhibiteur de la bêta-lactamase, au moins l'un d'entre eux se trouvant sous la forme de mini-comprimés

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020946A1 (fr) * 1994-02-04 1995-08-10 Smithkline Beecham Plc Comprimes de type bi-couche a base d'amoxycilline
WO1995028148A1 (fr) * 1994-04-14 1995-10-26 Smithkline Beecham Plc Formulation pharmaceutique
EP1285649A1 (fr) * 2001-08-23 2003-02-26 Cimex AG Comprimé dispersible à deux couches comprenant de l'amoxicilline et du clavulanate dans des couches séparées

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020946A1 (fr) * 1994-02-04 1995-08-10 Smithkline Beecham Plc Comprimes de type bi-couche a base d'amoxycilline
WO1995028148A1 (fr) * 1994-04-14 1995-10-26 Smithkline Beecham Plc Formulation pharmaceutique
EP1285649A1 (fr) * 2001-08-23 2003-02-26 Cimex AG Comprimé dispersible à deux couches comprenant de l'amoxicilline et du clavulanate dans des couches séparées

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014033077A1 (fr) 2012-08-28 2014-03-06 Dsm Sinochem Pharmaceuticals Netherlands B.V. Composition comprenant un antibiotique et un inhibiteur de la bêta-lactamase, au moins l'un d'entre eux se trouvant sous la forme de mini-comprimés

Also Published As

Publication number Publication date
WO2007059916A3 (fr) 2008-01-10

Similar Documents

Publication Publication Date Title
CA2186039C (fr) Nouvelle forme galenique pharmaceutique orale
US6299903B1 (en) Delayed release pharmaceutical formulation containing a β-lactam antibiotic
RU2170090C2 (ru) Способ получения фармацевтической лекарственной формы, способ ингибирования секреции кислоты в желудке у млекопитающих и человека
US6726927B2 (en) Preparation of enteric pharmaceutical dosage forms for omerprazole and lansoprazole
US6932981B2 (en) Rapidly disintegrating sustained release cefuroxime axetil composition
KR100421347B1 (ko) 약학 혼합 제제
MXPA96004354A (en) New form of pharmaceutical dosage or
US6663890B2 (en) Metronidazole antibiotic product, use and formulation thereof
PL190684B1 (pl) Sposób stabilizowania substancji aktywnych, którymi sa pochodne benzimidazolowe, preparat farmaceutyczny o kontrolowanym uwalnianiu tych substancji aktywnych oraz sposób wytwarzania tego preparatu
EA001537B1 (ru) Гранулят для получения быстрораспадающихся и быстрорастворяющихся композиций, содержащих большое количество лекарственного средства
JP2002523443A (ja) オメプラゾール製剤
EP0801559B1 (fr) Procedes de preparation des formes galeniques orales contenant un antibiotique du type beta-lactame
WO2018167589A1 (fr) Composition pharmaceutique comprenant de la dapagliflozine
EP1830819A1 (fr) Composition pharmaceutique stable contenant de l'amoxicilline et de l'acide clavulanique
US20070104789A1 (en) Gastro-resistant and ethanol-resistant controlled-release formulations comprising hydromorphone
US20080139526A1 (en) Modified release dosage forms of amoxicillin
KR20190015329A (ko) 다파글리플로진 공결정의 약학 조성물
AU2002359768A1 (en) Antibiotic product, use and formulation thereof
US20100029743A1 (en) Atorvastatin pharmaceutical compositions
WO2007059916A2 (fr) Composition pharmaceutique
KR20060030480A (ko) 플루바스타틴 및 카르멜로스 칼슘을 포함하는 정제
JP2000516601A (ja) 水溶性化合物及びセルロースを含有する粒状物
WO2023128898A1 (fr) Compositions pharmaceutiques comprenant du macitentan comme principe actif et d'autres excipients pertinents
WO2006100574A1 (fr) Granules de cefditoren pivoxil amorphe et procedes d'elaboration correspondants
HU221849B1 (hu) HMG-CoA reduktáz inhibitor fluvasztatint tartalmazó stabilizált gyógyszerkészítmények

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06818697

Country of ref document: EP

Kind code of ref document: A2